Abstract. Xeroderma pigmentosum group A (XPA) is a hereditary disorder characterized by cutaneous symptoms and progressive neurodegeneration. Since XPA patients exhibit peripheral neuropathy, neuronal deafness, rigidity, dysphagia, and laryngeal dystonia, it is indispensable for investigation of the neurodegeneration to analyze brainstem and basal ganglia lesions clinically and pathologically; we have previously shown the role of oxidative stress in the development of basal ganglia lesions. Here we immunohistochemically examined the expression of neurotransmitters, calcium-binding proteins, and neuropeptides in the brainstem, basal ganglia, and thalamus in 5 XPA autopsy cases. In the brainstem, immunoreactivity for tyrosine hydroxylase, tryptophan hydroxylase, and calbindin-D28K was severely reduced throughout the brainstem in all the XPA cases. Nevertheless, the expressions of parvalbumin, substance P, and methionine-enkephalin in the brainstem were comparatively preserved; the exception being reduced immunoreactivity for them in the cochlear and dorsal column nuclei in 3 cases. The large cell neurons in the putamen were preferentially reduced, the immunoreactivity for tyrosine hydroxylase reflecting the dopaminergic afferent and efferent pathways was severely affected, and the expression of 3 calcium binding proteins (i.e. parvalbumin, calbindin-D28K, and calretinin) was disturbed in various ways. The expression of substance P and methionine-enkephalin, which are involved in the efferent pathways in the basal ganglia, in the globus pallidus and substantia nigra was spared. It is speculated that the selective damage to the dopamine system in the basal ganglia and the disturbed monoaminergic expression in the brainstem could be related to clinical abnormalities such as the rigidity, laryngeal dystonia, and several neurophysiological changes. Functional analysis of autopsy brains will facilitate clarification of the pathogenesis of the neurodegeneration in XPA.
INTRODUCTION
Xeroderma pigmentosum group A (XPA) is a rare hereditary disorder characterized by cutaneous hypersensitivity to sunlight and progressive neurological disturbances, including peripheral neuropathy, deafness, spasticity, rigidity, dysarthria, dysphagia, and severe mental delay (1) . Protection from ultraviolet light can prevent the development of skin lesions, whereas neurodegeneration has never been relieved. One can mimic cutaneous lesions but not neurological abnormalities in XPA knockout mouse (2, 3) . We have neuropathologically investigated XPA, and clarified the involvement of apoptotic neuronal death, oxidative stress, and disturbed glutamate transport in the neurodegeneration (4) (5) (6) . In particular, the oxidative damage was predominant in the basal ganglia, which may be related to the extrapyramidal abnormalities such as rigidity and dysarthria. These findings suggest the possibility of treatment with antioxidant agents for some of the neurological disturbances in XPA.
On the other hand, we have performed neurophysiological analysis involving sleep polysomnography and evoked potentials, and revealed various disturbances of brainstem functional parameters (7) (8) (9) . The data strongly indicate that XPA patients suffer from various functional disturbances of the brainstem in addition to the wellknown neuronal deafness, dysarthria, and dysphagia. Nevertheless, since XPA occurs preferentially in Japan, the mechanism of neurodegeneration has rarely been studied in other countries. Recently, immunohistochemical analysis of autopsy specimens has allowed identification of the functional disturbances in both the brainstem (10, 11) and basal ganglia (12, 13) . Also, we have immunohistochemically clarified the functional disturbances in the brainstem in the case of infantile spasms (14) and in the basal ganglia in the case of alobar holoprosencephaly (15) . In order to contribute to exploitation of new treatments, we immunohistochemically examined the expression of functional markers, including neurotransmitters, neuropeptides, and calcium binding proteins in the brainstem and basal ganglia in the autopsied brains from XPA cases.
MATERIALS AND METHODS

Subjects
The clinical subjects comprised 5 cases of XPA and 15 controls without any pathological changes in the central nervous system aged from 7 to 74 years ( Table 1) . The clinical findings
Immunohistochemistry
Serial 6-m-thick sections were cut from selected brain regions, including the basal ganglia with the thalamus, the upper and lower midbrain, and the upper, middle and lower portions of both the pons and medulla oblongata. After microwave antigen retrieval, each section was treated with mouse monoclonal antibodies to tyrosine hydroxylase (Affinity Bioreagents, Inc., Golden, CO), tryptophan hydroxylase (Oncogen Research Product, Cambridge, MA), parvalbumin (Sigma-Aldrich, St. Louis, MO), and calbindin-D28K and calretinin (Novocastra Laboratories, Newcastle upon Tyne, UK), in addition to rabbit polyclonal antibodies to substance P (Zymed Laboratories, Foster City, CA) and methionine-enkephalin (Chemicon International, Inc., Temecula, CA) at the following concentrations; 1: 100 (tryptophan hydroxylase, parvalbumin, calbindin-D28K, calretinin and substance P), 1:400 (tyrosine hydroxylase), and 1:1,000 (methionine-enkephalin). Antibody binding was visualized by means of the avidin-biotin-immunoperoxidase complex method (Nichirei, Tokyo, Japan) following the manufacturer's protocol. Antibodies to tryptophan hydroxylase and calretinin were applied only for the brainstem and basal ganglia sections, respectively. No staining was detected in sections in the absence of an antibody.
Quantitative Evaluation and Data Analysis
The numbers of small and large cells in the putamen were determined in 10-m-thick Klüver-Barrera-stained sections for the XPA cases and 9 controls ( Table 1) . The small neurons could be distinguished from the large ones by the difference in diameter (10 to 15 m versus 30 or more), shape (round versus multipolar), and staining pattern (hypochromatic versus hyperchromatic), as reported in the literature (16) . The numbers of cells with an obvious nucleolus were determined in 10 microscopic subfields (1 mm 2 ) at a final magnification of ϫ100, and the mean value was calculated for each subject. On immunohistochemistry for tyrosine hydroxylase and tryptophan hydroxylase in the brainstem, the numbers of whole immunoreactive cells among appropriate cells with nucleoli were determined in 2 serial sections, and the mean value was calculated for each brainstem region except the substantia nigra. The number of cells immunoreactive for tyrosine hydroxylase in the dorsolateral tier of the substantia nigra was determined at ϫ100 magnification using a counting box (1 mm 2 ), because there were no apparent differences in neuronal density between the dorsomedial and ventromedial tiers of the substantia nigra in the XPA cases (data not shown). The substantia nigra, locus ceruleus, dorsal vagal nucleus, and lateral medullary tegmentum were examined on the right side because routine histochemistry revealed no significant right-left differences in the XPA patients, and for some of the controls only right side specimen were available. Two neuropathologists (MH, SA) independently performed both visual inspection of the staining intensity and quantitative evaluation of the putaminal neurons and brainstem immunoreactive cells without knowledge of the diagnosis. The inter-measurement coefficient of variation was under 5% in all cases. We used t-tests to compare the results between the XPA cases and controls for quantitative evaluation of immunoreactive cells, the level of significance being set at p Ͻ 0.01 to adjust for multiple comparisons. In addition, the average number of immunoreactive cells was graded into the 3 levels being compared with the averaged cell numbers in the controls (c-mean) as follows: normal (Ϫ), those between cmean minus 2SD and c-mean plus 2SD; a mild change (1ϩ), those between c-mean minus 2SD and c-mean minus 3SD; a severe change (2ϩ), those less than c-mean minus 3SD (Table  1) . On immunohistochemistry for calcium-binding proteins and neuropeptides, with the agreement of 2 neuropathologists (MH, SA), the degree of immunoreactivity of each marker was qualitatively graded as to the density of neurons and neuronal fibers, in comparison with that in controls as follows: (-), not altered; (1ϩ), mildly attenuated; or (2ϩ), severely reduced or absent (Tables 2, 3 ).
RESULTS
Analysis of the Brainstem Exclusive of the Substantia Nigra
On routine histochemistry, severe neuronal loss with gliosis was found in the locus ceruleus, inferior olivary nucleus, and some nuclei of cranial nerves such as the oculomotor, trochlear, abducent, facial, vestibular, hypoglossal and dorsal vagal nuclei in the 5 XPA cases, as described in our previous paper (5). Cases 1, 2, and 3 exhibited moderate neuronal loss in the solitary nucleus, but there were no changes in cases 4 and 5. In contrast, the neurons were comparatively preserved and gliosis was absent or minimum in the red nucleus, pontine nucleus, spinal nucleus of the trigeminal nucleus, and ambiguous nucleus. Also, the superior, middle and inferior cerebellar peduncles, the medial and lateral lemniscus, and the medial longitudinal fasciculus in addition to the brainstem pyramidal tract seemed to be comparatively spared and proportional to the size of each cross-section in the brainstem, although the whole brainstem exhibited a reduced area of horizontal sections when compared with that in controls.
On immunohistochemistry, neurons and neuronal processes immunoreactive for tyrosine hydroxylase were found in the central gray matter in the midbrain, the locus ceruleus in the pons, and the dorsal vagal nucleus and lateral tegmentum in the medulla oblongata in the controls ( Fig. 1A ; Table 1 ). Also, neurons immunoreactive for tryptophan hydroxylase were observed in the raphe nuclei including the supratrochlear nucleus in the lower midbrain, the superior central nucleus at the junction of the midbrain and pons, and the nuclei raphe magnus/obscure and lateral tegmentum in the medulla oblongata ( Fig. 1B ; Table 1 ). The 5 XPA cases exhibited a severe and significant reduction of immunoreactivity for both tyrosine hydroxylase and tryptophan hydroxylase (p Ͻ 
The averaged number of neurons immunoreactive for tyrosine hydroxylase and tryptophan hydroxylase is shown for each brain region except the dorsolateral substantia nigra, for which the averaged cell density of tyrosine hydroxylase-immunoreactive neurons (/mm 2 ) is presented. The mean numbers of immunoreactive cells in the XPA cases were graded as follows: normal (Ϫ) ϭ between the averaged mean minus 2SD and mean plus 2SD of the cell number in the controls; a mild change (1ϩ) ϭ less than the averaged mean minus 2SD and over the averaged mean minus 3SD; and a severe change (2ϩ) ϭ less than the averaged mean minus 3SD. Abbreviations: yr, years; n/a, not available; MH, malignant hyperthermia; DIC, disseminated intravascular coagulation; GBS, Guillain-Barré syndrome.
0.001) throughout the brainstem, although the change seemed to be milder in the medulla oblongata ( Fig. 1C,  D ; Table 1 ). Anti-parvalbumin immunostaining visualized the red nucleus, superior cerebellar peduncle, and dorsal column nucleus, in addition to the brainstem auditory tract including the inferior colliculus, lateral lemniscus, superior olivary complex, and cochlear-vestibular nuclei in the controls (Fig. 1E) . XPA cases 1, 2, and 4 showed reduced immunoreactivity for parvalbumin in the cochlear/vestibular nuclei and dorsal column nuclei, whereas it was comparatively well preserved in the other brainstem regions, including the brainstem auditory tract above the medulla oblongata in all the XPA cases ( Fig.  1F ; Table 2 ). Anti-calbindin-D28K immunostaining visualized the central gray matter of the midbrain, trochlear nucleus medial and lateral parabrachial nuclei, pontine raphe nuclei, and cochlear-vestibular nuclei in the controls. The XPA cases exhibited moderate to severe reduction of immunoreactivity for calbindin-D28K throughout the brainstem, the exception being the cochlear-vestibular nuclei in case 3 and the parabrachial nucleus in case 5 ( Fig. 1G; Table 2 ). On immunohistochemistry for both substance P and methionine-enkephalin, the neuropil and small neuronal fibers were found to be immunoreactive in the central gray matter of the midbrain, medial and lateral parabrachial nuclei, dorsal vagal nucleus, and spinal trigeminal nuclei in the controls. XPA case 4 only exhibited a mild reduction in immunoreactivity for both substance P and methionine-enkephalin in the central gray matter of the midbrain, whereas the other 4 XPA cases exhibited completely preserved expression of these 2 neuropeptides (Fig. 1H) . Analysis of the Substantia Nigra, Basal Ganglia, and Thalamus
On routine histochemistry, the XPA cases showed severe neuronal loss with gliosis in the substantia nigra and/ or thalamus, while neuronal loss and gliosis seemed to be milder in the striatum and globus pallidus, as reported previously (5) . Furthermore, the subthalamic nucleus seemed to be smaller than that in the controls, but the gliosis was subtle. In the putamen of the 10 controls, the mean Ϯ SD of the density of large and small neurons were 2.2 Ϯ 0.3/mm 2 and 69.9 Ϯ 2.6/mm 2 , respectively (Table 1) , although there was no age-dependent decrease in the number of either type of neuron, as described previously (16) . The XPA cases exhibited a severe and significant reduction in the number of large cells (p Ͻ 0.001), the mean of which was under the mean minus 3SD for the controls, whereas the number of small cells was comparatively well preserved (Table 1) .
On immunohistochemistry for tyrosine hydroxylase, the pencil fibers and neuropil in the striatum, the lenticulate fibers, and the medial and lateral medullary laminae and/or the neurons in the substantia nigra were found to be immunoreactive in the controls (Fig. 2A ). In contrast, the 5 XPA cases showed a moderate to severe reduction in its immunoreactivity throughout the striatum, globus pallidus, and substantia nigra including the nigrostriatal inputs and striatal output pathways ( Fig. 2B ; Table  3 ). Regarding the expression of calcium binding proteins in the controls, anti-parvalbumin immunostaining visualized the neuropil in the rostral putamen, the pallidal neurons, and the neurons and the neuropil in both the lateral thalamic nucleus and the subthalamic nucleus. The XPA patients exhibited a mild and severe reduction in immunoreactivity for parvalbumin in the thalamic and pallidal neurons, respectively (Table 3) , while the antiparvalbumin immunoreactivity was comparatively spared in the subthalamic nucleus in XPA cases 2, 4, and 5. The controls exhibited immunoreactivity for calbindin-D28K in the striatal interneurons and the neuropil, the pallidal fibers, and the pars reticulata in the substantia nigra (Fig.  2C) , all of which were more or less disturbed in the XPA cases (Table 3) . Anti-calretinin immunostaining recognized some of the striatal interneurons, the lenticulate fasciculi, the medullary laminae, a few of the pallidal neurons, the neurons, and neuropil in the intralaminar and 8 (A, ϫ100) . Immunohistochemistry for tryptophan hydroxylase also revealed the neurons in the medullary raphe nucleus in control 7 (B, ϫ100). XPA cases 5 and 4 exhibited a severe reduction in immunoreactive cells for tyrosine hydroxylase (C, ϫ100) and tryptophan hydroxylase (D, ϫ100), respectively. Anti-parvalbumin immunostaining revealed the posterior funicular nucleus in control 2 (E, ϫ100) and the inferior colliculus in case 1 (F, ϫ100), while anti-calbindin-D28K immunostaining revealed the vestibular nucleus in case 3 (G, ϫ200). The spinal trigeminal nucleus in case 3 (H, ϫ200) was immunoreactive for methionine-enkephalin. reticular thalamic nuclei, and the neurons and neuropil in the pars compacta of the substantia nigra. In the XPA cases, the anti-calretinin immunoreactivity seemed to be comparatively well preserved, the exception being the mild reduction in the lenticulate fasciculus in XPA cases 2 and 5 (Fig. 2D) . In the control cases, immunoreactivity for substance P was found in the fine fibers throughout the internal segment of the globus pallidus in addition to the pars reticulata and, to a lesser extent, the pars compacta in the substantia nigra. Also, anti-methionine-enkephalin immunostaining visualized the fine fibers intensely and lightly in the external and internal segments of the globus pallidus, respectively, in addition to the fine fibers in the substantia nigra, predominantly in the pars compacta, and a few small interneurons in the putamen. The XPA cases also exhibited preserved immunoreactivity for both substance P and methionine-enkephalin (Fig.  2E, F) . However, case 4 was an exception, this immunoreactivity in the substantia nigra being mildly reduced.
DISCUSSION
Previously, Mimaki et al summarized the neurological manifestations in Japanese XPA patients including CT abnormalities (17, 18) , and they reported choreoathetosis, dysarthria, and brainstem atrophy of the basal ganglia and/or brainstem lesions. In addition, Japanese XPA patients tend to suffer from rigidity, dysphagia, and laryngeal dystonia at the advanced disease stage, the latter 2 manifestations resembling those observed in patients with adult-onset extrapyramidal disorders (unpublished data). We neurophysiologically analyzed the brainstem functions in XPA patients (8, 9) . Regarding auditory brainstem responses, early wave components originating from the cochlear nerves and nuclei vanished between the ages of 4 years and 10 years, although the I-V interpeak latency reflecting brainstem conduction was comparatively well preserved (9) . This well corresponded with the preservation of immunoreactivity for parvalbumin in the brainstem auditory tracts overlying the cochlear nucleus observed in this analysis. Sleep polysomnography revealed sleep apnea in addition to altered sleep parameters. The patients below 14 years and those over 16 years showed the central and mixed types of sleep apnea, respectively (7). Even the patients below 4 years did not exhibit any abnormalities in EEG, auditory brainstem responses, or motor nerve conduction, whereas they showed disturbances in the tonic and phasic motor inhibition during rapid eye movement sleep, which may indicate brainstem functional dysfunction (8) . The amount of rapid eye movements and frequencies of phasic motor activities during rapid eye movement sleep were additionally affected in the patients at the advanced disease stage. The immunoreactivity for both tyrosine hydroxylase and tryptophan hydroxylase was severely reduced in the XPA patients in contrast to the preserved immunoreactivity for neuropeptides, and these changes might indicate disturbances of the catecholaminergic and serotonergic neuron systems in the brainstem. Similar altered expression of tyrosine hydroxylase and tryptophan hydroxylase in the brainstem has been speculated to be involved in the abnormalities of respiration control and sleep cycle formation in various neurological disorders (10, 11) . Since sleep parameters (which were altered in the XPA patient) are supposed to originate from a center located in the pons or medulla oblongata (19) , the selective disturbance of monoaminergic expression observed in this analysis could be involved in the dysfunction of the respiratory and motor centers in the brainstem. On the other hand, since the expression of parvalbumin and calbindin-D28K has not been fully examined, except in the substantia nigra and auditory tract in the human brainstem (20) , the clinical and/or pathological significance of the predominant disturbance in the expression of calbindin-D28K in the XPA cases remains to be discussed. However, it is noteworthy that the expression of calcium-binding proteins was differently affected even in the XPA cases, which may be generally speculated to have diffuse neuronal damage (5) .
The neurochemical organization of the basal ganglia has been intensively investigated in normal subjects and cases of neurodegenerative disorders (21) . In particular, tyrosine hydroxylase, substance P, methionine enkephalin, and calcium-binding proteins have been used as wellestablished functional markers for investigation of human basal ganglia. Immunohistochemistry for tyrosine hydroxylase can visualize dopaminergic innervation in the striatum and globus pallidus in healthy and diseased brains (22, 23) . Furthermore, the nigrostriatal tyrosine hydroxylase-immunoreactive collaterals reflect the dopaminergic output pathways of the basal ganglia, including the lenticular fasciculus. All of the XPA cases exhibited 
The degree of immunoreactivity was graded as to the density of neurons and neuronal fibers as follows:
Ϫ ϭ not altered; 1ϩ ϭ mildly attenuated; and 2ϩ ϭ severely reduced or absent. 
The degree of immunoreactivity was graded as to the density of neurons and neuronal fibers as follows: Representative illustrations of immunohistological analysis of the substantia nigra, basal ganglia, and thalamus. The neuropil of the putamen was immunoreactive for tyrosine hydroxylase in control 5 (A, ϫ100), whereas case 2 showed a severe reduction in this immunoreactivity (B, ϫ100). Regarding the expression of calcium-binding proteins, the striatal interneurons and the neuropil in control 5 (C, ϫ200) and the lateral medullary lamina in case 3 (D, ϫ200) were immunoreactive for calbindin-D28 and calretinin, respectively. Immunostaining for substance P and methionine-enkephalin well demonstrated the medial and lateral segments of the globus pallidus in cases 2 (E, ϫ40) and 3 (F, ϫ40), respectively. a severe reduction in immunoreactivity for tyrosine hydroxylase in the substantia nigra, striatum, and striatal output pathways, as in the brainstem catecholaminergic neuron system. In the striatum, as many as 95% of the neurons are medium-sized and spiny, the majority of which are projections and contain GABA, substance P, enkephalin, and calbindin-D28K (21) . Neurons other than the spiny ones consist mainly of large, aspiny interneurons making synaptic contacts with tyrosine hydroxylaseimmunoreactive axons of the nigrostriatal system. The severe decrease in the large cell neurons observed in the XPA cases could indicate a reduction in large aspiny interneurons in the striatum, which may be related to the disturbed expression of tyrosine hydroxylase in the striatum. Overall, the dopamine system including the nigrostriatal input, intra-striatal connections, and striatal outputs is severely impaired in XPA like in Parkinson disease (24) . In contrast, the preferential expression of substance P and methionine-enkephalin was well preserved in both the substantia nigra and globus pallidus in the XPA cases, suggesting the relative sparing of the striato-pallidal and striato-nigral projections, which are significantly involved in the direct and indirect output pathways of the basal ganglia. Interestingly, the expression of these 2 neuropeptides was also preserved in the brainstem (e.g. parabrachial and spinal trigeminal nuclei), in sharp contrast to the severe involvement of monoaminergic neurons systems in the brainstem. This strongly suggests the possibility of treatment with dopamine and/ or serotonin agonists for motor and respiratory abnormalities in XPA. On the other hand, it has been established that calcium-binding proteins label different groups of neurons and subregions in the basal ganglia (25, 26) . Calbindin-D28K labels medium-sized spiny projection neurons, while parvalbumin and calretinin label 2 separate classes of aspiny interneurons in the striatum. In the globus pallidus, most neurons contain parvalbumin but not calbindin, and calretinin occurs in a few neurons. The subthalamic nucleus preferentially expresses parvalbumin. In the substantia nigra, dopaminergic neurons express calbindin or calretinin in the pars compacta, while parvalbumin is confined to the pars reticulata. The expression of calcium-binding proteins was variously disturbed in the XPA cases. The immunoreactivity for calbindin-D28K was most severely affected in most of the cases, while that for calretinin was comparatively well preserved in all the cases. The disturbance in the immunoreactivity for parvalbumin seemed to be intermediate, and the preserved expression of parvalbumin in the subthalamic nucleus may also suggest the aforementioned relative sparing of the indirect pathway in the basal ganglia.
The present data show that the neurodegeneration in XPA can be selective and system-specific in some brain regions, although diffuse impairment in the central nervous system mimicking multiple system atrophy has been observed frequently (5) . Thus, it is strongly suggested that therapeutic interventions such as treatment with monoaminergic agents and antioxidants can be effective for relieving neurological abnormalities even in the advanced disease stage in XPA. We also believe that functional analysis of other brain regions, including the cerebral cortex and diencephalon in autopsied specimens, will provide us with hints for clarifying the pathogenesis of the neurodegeneration and exploitation of new treatments for XPA.
